Nitzan Rosenfeld is a Senior Group Leader at Cancer Research UK Cambridge Institute. He is a pioneer and world leader in developing liquid biopsy tests for cancer using circulating tumour DNA. He has developed multiple clinical diagnostic tests for cancer, based on microRNA expression profiling and on circulating cell-free tumour DNA in plasma. He co-founded Inivata Ltd., one of the UK’s leading genomics companies that was amongst the first to offer clinical liquid biopsy tests for cancer genomic profiling. His research group continues to develop sensitive methods for detection of cell free tumour DNA in body fluids, and ways to apply these for cancer detection and monitoring.